Impact of long-acting therapies on the global HIV epidemic

Nomathemba C. Chandiwana, Celicia M. Serenata, Andrew Owen, Steve Rannard, Carmen Perez Casas, Cherise Scott, Andrew Hill, Polly Clayden, Charles Flexner

Research output: Contribution to journalArticlepeer-review


Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may improve dosing convenience, tolerability and cost compared with current dailybased oral therapy. They can also circumvent stigma associated with oral therapy for both treatment and PrEP, thereby improving adherence and outcomes. Yet, multiple challenges remain, many specific to low-income and middle-income countries (LMICs), where the epidemic is most concentrated and HIV prevention and treatment options are limited. To optimize the use of long-acting formulations, key outstanding questions must be addressed. Uncertain costing, scale-up manufacturing, complex delivery systems and implementation challenges are potential barriers when considering the scalability of long-acting ARVs for global use.

Original languageEnglish (US)
Pages (from-to)S137-S143
Issue numberSupplement 2
StatePublished - Dec 15 2021


  • Access and barriers
  • Long-acting antiretrovirals
  • Low-income and middle-income countries
  • Treatment optimization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'Impact of long-acting therapies on the global HIV epidemic'. Together they form a unique fingerprint.

Cite this